0000950170-21-004075.txt : 20211110 0000950170-21-004075.hdr.sgml : 20211110 20211110160702 ACCESSION NUMBER: 0000950170-21-004075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 211396562 BUSINESS ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: ONE NEWTON EXECUTIVE PARK STREET 2: SUITE 202 CITY: NEWTON STATE: MA ZIP: 02462 8-K 1 alna-20211110.htm 8-K 8-K
0001624658false00016246582021-11-102021-11-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2021

 

 

Allena Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38268

45-2729920

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Newton Executive Park

Suite 202

 

Newton, Massachusetts

 

02462

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 467-4577

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ALNA

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2021, Allena Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2021 and provided a business update. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information under this Item 2.02 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

 

Description

 

 

99.1

 

104

 

Press release of Allena Pharmaceuticals, Inc. (concerning financial results) dated November 10, 2021, furnished hereto.

 

Cover page Interactive Data File (embedded within Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Allena Pharmaceuticals, Inc.

 

 

 

 

Date:

November 10, 2021

By:

/s/ Richard Katz

 

 

 

Richard Katz, M.D.
Chief Financial Officer

 

 

 EX-99.1 2 alna-ex99_1.htm EX-99.1 EX-99.1

EXHIBIT 99.1

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

 

ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA
Two Phase 2a trials for ALLN-346 enrolling patients with gout and chronic kidney disease; initial data expected in Q1 2022
First interim analysis for URIROX-2 Phase 3 trial of reloxaliase for the treatment of enteric hyperoxaluria planned for Q1 2022
Registered direct offering completed in Q3 raising gross proceeds of $28.0 million

 

NEWTON, Mass., November 10, 2021 – Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the third quarter and nine months ended September 30, 2021, and highlighted recent corporate progress.

"We continue to make good progress advancing the clinical development of our two novel oral enzymes focusing on patients with urate and oxalate disorders," noted Louis Brenner, M.D., President and Chief Executive Officer of Allena. "We are pleased to have recently received Fast Track Designation for ALLN-346, our novel oral biologic for the treatment of hyperuricemia and gout in patients with chronic kidney disease. We believe that ALLN-346 has the potential to address a significant unmet medical need, as currently available agents are either dose-limited or contraindicated in this patient population due to safety and tolerability concerns. For reloxaliase, the most-advanced drug candidate in development for patients with enteric hyperoxaluria, we remain on track to conduct the first interim analysis of the pivotal Phase 3 URIROX-2 trial during Q1 2022."

Recent and Third Quarter Corporate Developments

Fast Track Designation Received for ALLN-346

In November, Allena announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). ALLN-346is in Phase 2 development for the treatment of hyperuricemia and gout in patients with advanced chronic kidney disease (CKD). In gout patients with advanced CKD, the intestinal tract becomes the primary route of elimination for urate, and ALLN-346 is specifically designed to capitalize on this physiologic adaptation by enhancing the breakdown and secretion of urate in the intestinal tract.

 

 

Initiation of Phase 2a Program for ALLN-346

During Q3 Allena initiated two Phase 2a studies of ALLN-346, study 201 and study 202. Study 201 is a one-week study being conducted at a clinical pharmacology unit (CPU) enrolling patients with hyperuricemia. Patients are to be randomized (2:1) to receive either five capsules of ALLN-346 or matching placebo three times daily.

Study 202 is a two-week, outpatient study expected to enroll 24 hyperuricemic patients with gout and mild-to-moderate CKD. Patients are to be randomized (2:1) to receive either five capsules of ALLN-346 or a matching placebo three times daily. Of the two currently planned cohorts of 12 patients each, one cohort will consist of patients with an estimated glomerular filtration rate (eGFR) of 60-89 mL/minute (CKD Stage 2), and the other will consist of patients with an eGFR of 30-59 mL/minute (CKD Stage 3).

For both studies, key bioactivity endpoints will include measurements of serum urate and urine uric acid. Both studies will also assess safety and tolerability in the hyperuricemia, gout and CKD patient populations.

Allena plans to report initial data from these studies beginning in Q1 2022. Initial data from the Phase 2a program will potentially assist the Company in determining the optimal dosing paradigm and target population for later stage clinical trials.

Updated Plan and Timing for First Interim Analysis of the URIROX-2 Phase 3 Trial

In July, the Company announced an updated plan and timing related to the first interim analysis of the URIROX-2 Phase 3 trial investigating reloxaliase, a first-in-class, orally administered, non-absorbed enzyme in development for enteric hyperoxaluria. Reloxaliase is being studied in the adaptive-design URIROX-2 trial, the second of two pivotal Phase 3 clinical trials in the URIROX program. The revised interim analysis, which will be conducted by an independent data monitoring committee, will assess whether the study continues to be adequately powered to evaluate efficacy against the primary endpoint, the change in urinary oxalate levels during weeks 1-4 versus baseline, with the planned enrollment of 200 subjects, or whether the study size should be increased. Any adjustment in study size would be designed to ensure that the statistical power of the study remains sufficiently robust. As previously planned, the interim analysis will also include an assessment of futility with respect to the primary endpoint.

$28.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

In July, Allena completed a registered direct offering priced at-the-market under Nasdaq rules. Net proceeds to the Company were $25.4 million after deducting placement agent fees and other offering expenses.

 

 

Third Quarter (Three-Month) 2021 Financial Results and Cash Position:

Research and Development Expenses: Research and development expense was $9.0 million for the third quarter of 2021 compared to $5.0 million for the third quarter of 2020. The increase was primarily due to increased costs incurred for the ALLN-346 program, including costs for the Phase 2a studies (Study 201 and Study 202), along with increased costs associated with the reloxaliase program, primarily related to the URIROX-2 trial.
General and Administrative Expenses: General and administrative expense was $3.4 million for the third quarter of 2021 compared to $3.0 million for the third quarter of 2020. The increase was primarily due to an increase in consulting and professional services costs and insurance costs.
Net Loss: Primarily reflecting the factors noted above, net loss was $12.7 million for the third quarter of 2021, compared to $8.0 million for the third quarter of 2020.
Cash Position: Total cash and cash equivalents as of September 30, 2021 was $40.4 million. This amount includes $25.4 million of net proceeds that the Company raised during the third quarter from a registered direct offering.

Year to Date (Nine-Month) 2021 Financial Results:

Research and Development Expenses: Research and development expense was $27.0 million for the nine months ended September 30, 2021 compared to $13.4 million for the nine months ended September 30, 2020. The increase was primarily due to increased costs incurred for the reloxaliase program, primarily related to the URIROX-2 trial, along with an increase in costs associated with the ALLN-346 program, including costs associated with the Phase 2a studies.
General and Administrative Expenses: General and administrative expense was $10.6 million for the nine months ended September 30, 2021 compared to $8.6 million for the nine months ended September 30, 2020. The increase was primarily due to an increase in consulting and professional services costs and insurance costs.
Net Loss: Primarily reflecting the factors noted above, net loss was $38.3 million for the nine months ended September 30 2021, compared to $22.6 million for the nine months ended September 30, 2020.

 

 

 

 

 

 

Allena Pharmaceuticals, Inc

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

 

 

 

 

 

 

As of
September 30,
2021

 

As of
December 31,
2020

Cash and cash equivalents

 

 $ 40,421

 

 $ 35,042

Working capital (1)

 

  34,281

 

  31,127

Total assets

 

  43,870

 

  38,931

Loan payable, net of current portion and discount

 

  9,893

 

  9,853

Total stockholders' equity

 

  26,030

 

  22,569

 

 

 

 

 

(1) The Company defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial statements for further detail regarding its current assets and current liabilities.

 

 

 

Allena Pharmaceuticals, Inc

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

For the Three Months Ended
September 30,

 

For the Nine Months Ended
September 30,

 

2021

 

2020

 

2021

 

2020

Operating expenses:

 

 

 

 

 

 

 

Research and development

 $ 9,024

 

 $ 4,952

 

 $ 26,966

 

 $ 13,406

General and administrative

  3,407

 

  2,966

 

  10,562

 

  8,595

Total operating expenses

  12,431

 

  7,918

 

  37,528

 

  22,001

Other expense, net

  (261)

 

  (108)

 

  (772)

 

  (586)

Net loss

 $ (12,692)

 

 $ (8,026)

 

 $ (38,300)

 

 $ (22,587)

Net loss per share attributable to common
stockholders—basic and diluted

 $ (0.17)

 

 $ (0.22)

 

 $ (0.61)

 

 $ (0.77)

Weighted-average common shares
outstanding—basic and diluted

  76,658,487

 

  36,260,973

 

  63,283,268

 

  29,317,787

 

 

 

 

 

 

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company leveraging its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, with a Phase 2a program recently initiated.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the future clinical, regulatory and commercial potential of reloxaliase and ALLN-346, statements regarding enrollment and the timing of the planned interim analysis in the URIROX-2 trial, the impact of an earlier initial interim analysis on the size and duration of the URIROX-2 trial, statements regarding Allena’s strategy of pursuing a BLA submission for reloxaliase based upon data from its URIROX program using the accelerated approval regulatory pathway, which strategy is predicated on the FDA’s agreement with our predictive model supporting a relationship between UOx levels and kidney stone formation rates, statements regarding Allena’s development of ALLN-346 including the timing of planned clinical trials and the announcement of topline data for these trials, and statements regarding Allena’s financial position and need for capital. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: market and other conditions, the timing for completion of Allena’s clinical trials of its product candidates, risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of reloxaliase and its ability to continue as a going concern; risks associated with Allena’s dependence on third parties; and risks related to the COVID-19 coronavirus. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Allena’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

 

 

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

 

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

 

 EX-101.SCH 3 alna-20211110.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 alna-20211110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 alna-20211110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 alna-20211110_htm.xml IDEA: XBRL DOCUMENT 0001624658 2021-11-10 2021-11-10 0001624658 false 8-K 2021-11-10 Allena Pharmaceuticals, Inc. DE 001-38268 45-2729920 One Newton Executive Park Suite 202 Newton MA 02462 (617) 467-4577 Not Applicable false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Nov. 10, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 10, 2021
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity Central Index Key 0001624658
Entity Emerging Growth Company true
Entity File Number 001-38268
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One One Newton Executive Park
Entity Address, Address Line Two Suite 202
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02462
City Area Code (617)
Local Phone Number 467-4577
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports alna-20211110.htm alna-20211110.xsd alna-20211110_lab.xml alna-20211110_pre.xml alna-ex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alna-20211110.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "alna-20211110.htm" ] }, "labelLink": { "local": [ "alna-20211110_lab.xml" ] }, "presentationLink": { "local": [ "alna-20211110_pre.xml" ] }, "schema": { "local": [ "alna-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20211110.htm", "contextRef": "C_fda98efc-7d4f-46de-9efe-aeb827ecff53", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alna-20211110.htm", "contextRef": "C_fda98efc-7d4f-46de-9efe-aeb827ecff53", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.allenapharma.com/20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0000950170-21-004075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-004075-xbrl.zip M4$L#!!0 ( ." :E-9YF<.HQ, !;, 1 86QN82TR,#(Q,3$Q,"YH M=&WM/6E7XTB2W_M7Y-*[_> M:>L^#,4\&J@>MJN Q?2;?OME7BHSA#4E2VY) M!CR_?B-3DK'!51C,(8/H R3E&7=D1&;N_NUF&),KR/(H33YMZ!UM@T#"4Q$E MEY\V]OL'Q\<;?]O;_0]*R>'GXQ-R M=DGQ?1%1Q&.8_3?)P!V>Q_W2+'21PE M0/[\]?P+.4SY> A)02@9%,6HU^U>7U]W1!@E>1J/"^PJ[_!TV"64EFT?9,#D M:W+("B ]0S-TJN._VH5N]72M9UH=RW?U_]:TGJ;=UDI'DRRZ'!1DDV\160E[ M3A*(XPGY'"4LX1&+2;_NP?_M!=E4LKG3;3;?(6)*':394I")' M85/-H(8STPC-8;YW?.Y3&+XM"&B?!2SB<0H[&SL[48W/5D1 M^+3Q^9^A, 3C$%+=<31J 7#*0L^AKF]99J"%FN^Q#9*PH>P%HMY1@E.9'. 0 M,Q8?)P)N?H=)->R;XAQ"G! VRGP/0DY=8874<@10'T*@# +/<(&'H6UN[&F( M'L>P'-O;[=!FF&]#$4PY'N[DAE[N2(W[(@HYNQ)%OJTD4?#42QI M3[T;9'(04I):=7%45%$+K MITC(YS""C*@AP$+>/#C^?1Y]=ROOU:_F6Q\A %-1/R$W9H74'WNWZJ.N=_MM M.DSQG:+UE_JY[J0[!YH:CE/ =6=XI(NLI%AJ5#.4K(("0TZHIW6T_]H)L1F: M1_\&U&X=;53L#%EV&26T2$>]\H445W0 4E'U](Y9U@C9,(HGO8MH"+G2Q>?I MD"5UY2 MBG18U5==LCBZ3'HQA(5DXWS$DGI$UX.H (IO./1&&=#KC(WNC^I' MG6[L_?*S[F@[NUW9+LYZ-#_G(,T0&FI&1L>PL3DBTG$0 \DN [:I;,?[O,TG$B*$_C-.O-8$K;VKGW M#K'W?4A=EP,-TEC,3LY; G1_G!Q?'!V2_L7^Q5%_-\A09?6/#OXX/[XX/NJ3 M_9-#G7[\>]_O'IR=EN1K>KSTM8XEI_6.___?CD]\N3D^V MR6'GH(,FJVWYWZ.0"H.2/'N6(I&5.<5X J=4;#Q]YRI.1CL^$G<8N:JM+/+9 M$:\-F^G/+GF;S6:?3\^_DD4,\\AV%MI7MLX,P[5-ZH>F3RW!T6!P0%#/LHTP M#'S78? D,VK&)JO]3&7K-A/&RERO:/.NX=?R?3/XWG\_;+^,&D)%>GYT3'T&L=5[R)A8IM.%Q@1S7$LXCD6!!T MF]O4 M\UR/,L]EG#&/6X[[7,;$F7+XC\IE@ U2+A1^VHANBI[ -T/L9"#89()0@*2A MF#M)KV 8 ,HC;5LMC#]L@]SCE4+I2?PV64 MR_A%<8)?7E_X+ 6C?17.(&+6'<[>I3KA#.5P/ZT@5K@ [I1C]#;3_DLHXZ!=(Y@>(QR*;'*1BWL>0"0PR M7%G *$NO9#N-=3(.(6;7Z 0]PK?XJ*L"KT+.KAEJMN';U+;U (G80R>9FP%U MF1TPT^0::,;SD//G* ;L&QW,AI*FING4] S':VFS&;0)EL9]5_.I[QH&M3C7 M*+,T03T_L)S0TRR?F<]#FQ?LYKA*'.%*W#::4"V;&J[A^X;VA!6:!8:$NZ9V MA/M&M-T49T[9!#* <%H,("/_,\ZB7$0JLE#F-:"+-V=$;*VC"/OH6#Y(A\,H MEZG61*I04HJF%I5KB,KC\SXY&H[B= )9R:'S6H>S.UYD MX6)M&*P%>POV%NPMV%NP/Q[L[4IKP]Q_'PS?8ZY.-:8+:MD6T,#2;0JF'3++ M-(6P5TX&+=W_?2$RR//JUQ<$CMY0U_\T ?E#] M4XP&G#E@^=3T?9=:S$#N$H%- ]/2]$!S6>@]TV+F?8HQ&DHQ_3$V*M-Y'KNJ M.15Q1BOB6FVTUJAZ#MD26+YC&%RGM@% +8-SZG.4,J%MZZ YEA&ZSQ3WJX3* M ?YYFEVDUTT-Y95ZZ &QTL2!;[]8RJD#@H>Z[U ;+ U-EM! 7)LF1?0+'[\X MFNX_*Y&H)>#3["Q+KR*UK7P]H\)?69XS/ACG4!1Y \-O#9)PKY:M\ZI +F?[ M,36+QC6+ ]JJ3+,M:H%F4R]P@#K@A,+10R,,Q;,*C;,4I4+\?]%()9(T4R)H MAN4\QF1MPYOO+EI24:M,5#W+4+M%(Q;/>+VG81AQR-=E7>[M3XY><; [W(G9Q<0 RC M09K4*2%JLTP\E@@D^X@IQ>J]UW+$$^EXQH^=UXMYXA[W7<<5/F6FS:BE,Z"> MC3YY(+CN&P$'S^.K&M5RA48"NL%F]*:CNUMOO$33,,H0NO"%#A8UF&U32T-4 M>Z"[%)CEFL)W;&/UK-(O*8K&,\F;S4XD=5QJV:[[7!M]6RNAM1+6S4IXG24> MAP>.Q1GU;6%2B_L:9:[E4!>%BA?8C =A^%R;AJ:'E'[&/R#[ IJY67;1*%5$=[?%RVX+-N^<6/E$Q?*!]P0N MN)A2HLFW1SK\& _)LZ+XF- M1EDZRB*Y%2)(;T@ <7HM"5=^E/1,//H["5%_HEL4Y2229QL+).@B)7DT',<% M2R =Y_&$Y"@V\W"B:E85T@"!4>9F5^=C-+8MPZZX M[LY1:?*$M$W=)0>?SXEA:ATL>*N?ZI.55R-]9ZU)WP#F^28X--"$)DD?;5'= M-:FI:6,&N![U#("BP8V=R@8MF]9O@"+K9S(>([O^3[:^U22$O\^,X98#7X@#+S(F,5+=H#,98AN;;YMEV;)? MRWX?AOU*OCNI3NA5^@]J2QYM2NP3W]P:GBOO'6QPNNY:A_Q-",S =DSJ.S[Z M6WIH4\\U3:I9H6."QH5CK[P5K')%)KH1*(NIN>$Z=%^1>/M%RK]M$_13R!6+ MQT#^$RMK.AG)JQX'S3P5M$'$^GXUR8>4$-QQ?2_4@8;"06X/0HUZ*#.HQ1P> M6J!I@;7R0EQES)5F7&/%P_Z7D_V6]5O6_S"LK]FFS?7 H:ZI,VIY(<(J=!QJ MZ"@3#!M$Z*V<@UP;!_4ZL,K[N[?N+FW+5]L:_C3I<++?/]S_7_);G 8L)GV( M@1?D*\N^0?$F*8+5;6\OS-W-@?]Q(F3@ 4@P(5SE7>%TOJ$G NK8V3M)45%. MZH MG2]&N*/R.^I*V!V2]TA>4R(3&,M@B!%08\G[].XU+@,DM_5GFN\T+)&K(==6 M-IMVC[Y#ATMM+OG>(1^&9^DFLZBK.P9Z=HZ0AWP8U!>@"XN!H6DKWRM7)G/7 MH_]-#?Z@'/O+QTZ=!V.G+04N+SW#'\C#;92""X5K="_9=("B4ZD^%)U)JN*, MXQQ4*01%E=**)?-(Q1Y'ZD)"22JJKW@B.[^.L&M)_@D.$+]D;S-9#:@H7&0:8 M39DKD,ETS_(<\#7373EMIV*RFXLIV,IK'->=P^X;PJC35LZ?-ZKU79&.9=AZ MGGG6*UM^?=TS.>?!=%%WQ"ZA=+(H"]%&Z;'XFDWRG0W2_;#0>:)-[ZTXZ3?; M/_&4&,-Q 4."7HQ!SB$?QX4Z8^4454:57H2"GWR>ZH2#%'64_-!9!M0H)ASW MQ\!>G#_W;BV 4WFN_YVK=;?)CRZ\1")0E.B*N= M+(BT6[6=56B4ZE[JX;_&ZN9&4IH%?4 '1G5O5MTK#$_5.B/!.$=L8$_CD;RN MN$,NY&Z6<1P3">5:N\\/!EVC<)PE43Z034CO:A %44%\OZ,3= P!C039332] M@03+R??H^*&QDZ%FSF1^6TM53Z(JB:'H=K/G-/$/T7++WG?V.P4PBS+$33Y MHT:9D_A) %JI@I0'3/"=,(I!E ]B1U$6FG^C- DH[TM:01-+S66 M35FA[FBV=-W?UK:T3U.YP'"-)BK)Q\&_Y+(/3D)6C2.F$MJBT MC=/)JHE%L_.:H\-9 I0K$=(HKK9\?7=_2;4<,3L1-*=G5ZUBZNW*B MJJ]U;,]L=*IJ77EZ%I*JOG:AEQ>3-*IG ;RZ)ZVG=(":KV(M\IABS?UF9^UL(B?EZ>/(2<9]%(78OXN&PY MN^/:#9'5#6?;5\A%>.7[*%HT/(Y3O)93UFP%02[4-/%^H-7X-/QQ2&&3IPF'+)%+G/<"!UM$J&71!7&*VP7C_.I'[*\+%;[=G*LS$M=F)V#_^+>3_8L_SH_Z#05?L_GX;"99KDUP6C+-BV06R"W0/XX0'X_ MQONJVGC-%L0.T5_LK2?;?#!,W5N^;[&V!EC[==*D.T(:=8I<2T-+8K";=\EY MQ-%A$N1W5OS[?2O@=V -M4!N@=P"^;6 ['ZHR->L(M@F7SN'G7(_PL$@@G!F M<]1I&$8=GS!7:[02HF>S_M=@?%,-[[?U!+ P04 " #@ M@&I3:P-='A<# #""0 $0 &%L;F$M,C R,3$Q,3 N>'-DO59M;]HP$/[> M7^'E4ZO->:$O6Z-"Q^Z1P$\_G< M3R>4*\$*;<(I/Q%9@#"NG=]((%:.>D0#BEMA*\*1^88/T5DP7_4Q!&)Q124V,&MCAK!@VU:0I7,? B:ZV"+L:2^4). M;: P@(4&KNB8 ;9F(,O2*=RR':S@A'%R*.4*85)? \Q/ZX!A%#S=#:K..F-& M^>\UZP;!\#2PZC%1X,P+A:>$Y"O$A*AQ:5TK2C(XC/!IY" IT/7L%23^5+P$ M1E&:KW@;9:JW52H\#RIETY3NH6W&4YN16=%>O$FS+DIT>7D9E%JO@4C*GNP)9O]A%Q%;$8Y:I@"^<>8AOG7N=M -_HV$Z]:'2*Q:_5$2 MKDDV^OFNN%N[>E!$M6M^[ ';P]Z8;Z;N?4&W#GH 3"LGP:^COXO(OFUYI4,X M%[KD8$5.F.>43T0E,3+;K=BU; @35 YQ3&0B!8/]HQ[D4N0@-0757/#2P4S" MI.W9APYVSY5G1L:^V2-G\B; ^AQ9=6 @P :O]!Q64VW! ZM6J-P[IUGF1J%, M+U@]@O\]SUS">_,T$&5N@+);N]/]U; Z.&GK_\'HD3T\#ON'70*!)@O!1;:L M^+G[V_UV>?J#&U;+OADF@[6,/$3-A3$TYL\'F3N:CF@*YG6 EO,:A?9C7A8: M[PVKHW&&*F^HX>XJV'2RX;Y0D/[DG?*\6>X:7)OL 2:$)05[/^Z5UDY8+73M MJG&-,E_?[;!-( A65)#I4JE\/C[?![ !KYZ M^OG+9A' $V(AIN2\Y;0[+4#$HSXFL_/6MY'5'PV&P]:7BS>??[,LN+P>WL$= M6D/?B_ 3NL2A%]!PQ1"\'=V^@^]_/M[ #28_)VZ(X))ZJP4B$5@PCZ)ES[;7 MZW7;GV(2TF 5\81AVZ,+&RPKD1\PY(K]<.E&"'K=3M>Q'/[3&3L?>DZG=_:A M_?',^?A'I]/K=':&T>66X=D\@K?>.Q"C>&Y"4!!LX1H3EWC8#6"DDKZ'(?': MT \">!2C0GA$(6)/R&_'F@&OH!>H,C8A[H7>'"W<&^I)O//63CV;"0O:E,WL M;J=S9J>C2B/$7Y8*L\0NR^E:9TY[$_HMX%>#A#+W 4E4^*80OSZ3T30-#;$ND,LZ]O?;FY<^)7*.)G#;4NW@ DI\.=H$!<6I!Z/48#5($H#MM) M8AD?X4@,2&72_=LEWXTV$2(^\F7"-"7U,D&!./V4J9%SAJ8Q0<@19/H0>>T9 M?;)]A&UQ&X@-2VR(D_L[_^/'@/)[O3\)(^9ZD5*24.>MXG';-$Z?SP]?S)'K MP)UI<++'C>,,<+3M\SDXH#[2G9S=P\9AU/+Q@!BF_A7QQ:*@H=+'U88WYHH5 M5/*P<9@K$HEKX_L,A6'RB\\RY&C(RF,;P^S^ F:W9DQQT]^S,5V3?9 [D?4B M/E"^7 ?_X&7)O*T(KA=T%/&I><\>&'W"XO&R!S4?7A/L@$];Y@9#_D#:?$7; M4LI\7$UX5PO$9OSU["]&U]%\0!=+EY1#ZJ/K0MV,F4M"+%Z:XN6YG+,86A/D M-0[0W6HQ0:P4;B>D)BC^ADK9DC+YOBGGP8"N^.VVK9SBU:-J0Y]2MI (UWP# ML1LT2IAH@1,QP[AH,QYY0+@%" X2(&4RMXW D;VJ2QF+ U:3[ M:99)$KOU89PJA'GE9"(@50#+F>2 M7.NGG,:O)"'6A$34:!4%M^7$$C;P+)@\RDSR/QLRIW$+'8B%3.)6^C*G59"1 MWIG%20+C:])A=LVI-:8YWD.AS(A"93-::=7E.J^E9RSAVB>US&C\7 MA:RJT7F4MX>.A)2 MR[% I^!TWT[>@5(UR[QK11W)K:1 :1E<>(HVU;'0J1 H)3/$&1/KV#LCUH!8 MQ RGUM4ZDC?1@JQ8)7>?90T]EWDJ,=_E MHV6F6]'1JP-2V[FC((M^6S.0NGZ>]$3FO;9F$"N[?!1KN>'6+/1N[T^>-;78 MFD'*O-MM<%WST4OOM:X(O=0UKTG+'V"L"U/45:]J*I]@KP2SJ-M 7H M_+0F2RCI/\JRZQRT)J$KNY*RZ.466J,%E/8JY>CUUEF3Z,4.IBQRSBUK$O6@ MOJ8L_7[SK-F"?J7;*5_9P=Y9DR7J>Z"RI6BLL2:1]W1&9=FK_+%FBBCKEU+< M6C>L&=1#NZ@4^D'.V*LHY? B7@=^6<>5@M;:7\VBZOJP\K@%YZLAY-+NK!18 M[WDU@ZOMV5*D1:^K&A=MXI_^?V\>*/VX/B?Y"[^!U!+ P04 M " #@@&I3U2L'^=(]^KC3*Z_+D).7D!I)D7+\FJN14#X,F!BTK*^ M#>SVH-/M6E]O+JY_LFUR>]]])(\P)VT_9B]PR[3/I9XI(!\&#Q_)]]_[/=)C MXI\1U4!NI3\+0<3$)M,XCIJ.,Y_/:\&8"2WY+,8.=]U\1P$U[\DM MC8$TZV[=LSW\=8?>9=-SFXW+VA?/O?K%=9NNNU5-1DO%)M.8?/ _$E,+^Q8" M.%^2>R:H\!GE9)!V^BOI"K]&VIR3OJFE21\TJ!<(:JLV.2IH\E3&0K.F]J<0 MTI[T$WHM:TO/8J1X3:J)4W?=AK.I58@PW^P49IM7ME>W&UYMH0.+X&P(G?3] MBDY2^.( /V\D:._JZLI)2C=0S?* V*SG?'_H#1*=-LY0C*,&ULT%(:OA4))# M'\;$/+_UNSN-4,Y!T&A*54B3&353@#^N$].%%#)<.J::DP9$^FR+X$[$+%YV MQ5AB73.V2#3I;ZI@W+(H%]1.6S,C]',?&_KQEH;B900M2[,PXF YF:!(X:2+ M.,&:D%W##=&SB\/7II=]"KN481&#""!()B%ES:6_ ^(F)*7:'37#7B/])&HT M^+6)?'$"8 EU\R$9TF0X\L@[+G7/3:>/H!68$ M[SF=Y-#9+3\[G0Y.81O7I8X,(&]PMHO/3B8-KF=03&)\!6:AS&&5CRN-WA!; M/,(J*3X[F57VM8, LTRO'YAEX.4P*\;^9S3K;Z!9+YFF"?HG-91S<8KD%K)< MBL\2MS#^-XL*\O8(N%RB US_X4D]*_G"S)9[@NH^O"2R'4Q;17D7-Z3%G[ L M9+F/*XG>70AJ@D?6/Y22[F>0@MB>0] MX_ X"T>@"LEM04HBA:=VJ2*IDO-2D@<=.<-P6QY-\>.U2J.^.0/>XP=0/9A0 M_J3Z,&$Z!@7!(PV/:7A5]9+$K'K%R(R/DMZ#E41N2!?= !%V1'B&2/%FE;-)O MHELJT0'X,X4QY]5'0W,#S*%W "F-U-W"GU(Q@8*<.%6 MC/(\:H>@LQ/#C=E89(-E.))YG';+ST[G+YR:&(2)[)E8+V0ZAU8^;H?>MBG1 M5KM4J?+31O'C@56RZU*M$4Y$%;9G^U/&-T>=L9)AGKF0]B;SKOI$*LS5EN6Y MKN<:HS+"(Y&)R9:%EZ691C(R,K3W ^#_)&G73M@H\AJ5553@26235:^\M)6? MD2ER*ZOHB"F2R;MZ=_+J._*\=R%OVX3)UI%W$II[]DVFK[J+R7'7)U-8W;VM MP"K*,N^RXM(*;*9,X*>J"\PQIS;JZE5?6[9=K6S./E=-H;S%16]P9QS$S,]%4W M-@\]R&Q_K^[),]_$W"AK5#?K\AS0+ ZKNZ7O&:A9$%;W@E=@PF:S];J3YK5S MH*R'+VXNU@7FC_GOOYM_ 5!+ P04 " #@@&I3I]\29K,= !0E@$ #P M &%L;F$M97@Y.5\Q+FAT;>U=:W?;-K;]/K\"*]/..&M1JD3Y(Y/+/!)O?_J]T>LUVV]^L+^BP0]EBS<#%4Y,RY3I?!*)?[W* MQ;>\(9-0)'F_U6Q]?SA42=[0\B_1;^/W-#^,>3:222-7:=]^$,E$-,9"CL9Y MO]WLV!Y#'LMHTC^5L=#LD[A@)RKF2=5YH/) M6KHN+)T#%87S2VL;2N8I?P>*!ID$,3_]_M\??OQPRBP3J=6?]CUQ7L?*?_R]O=\Z7%IO*,^KD4MR(C',^[O-O4[G M^\-0ZC3BD_XP$M\6U[L*NW\4.I?#"90%A(-MU*NA<\CFT*RH XRSH2O22R8 M3%@HSD6DTI@0/U09R\>"Y9G@N?E$#=EXDHJLR&0@8LF-?1BI(J>NU%2+/)?) MB!KR\!S&!(,'XTPE,F!G,DS$A(&S FKLL0QV19X#UN^YSMEI!IZR8Z&AH#R7 M*F'#3,7L_?$1F^(.\BG_=OAS^*L5_DXO%'E:+9C/ 1A)GI;P4^$2$,M4%!$V M4J@W.*79A0Y9^);*H(?FF3U_8=.APZZL&L M]>AX3QX).@MO(V-H.X\F6EJ _'KRX>3S[PV_1$_'@H<<2 9'] T#T,:'ONDSD4\$!EKMSQ;. . M_5:[<\A6UQP\]B$)FFSGT]'7XZ-?^@B*/AV]9CNV5W!H.]G?PD-6FOKJVW?0 M?IY,JJ]?4X83<5I"#:1*%V8S<$$'I#)II"8$%(E@*P'1D4E^J$ND1G < M,! YW$3,E0#8H4W$L,BJ)@$67$BLS6ID[@62PV-!@'5LHAT,9 M%%$.56D8O\5BD7.8/,Q<1G<8(U@T1 MET#Q6 QYC36H"-'[JTAS*YI.*1K/M!Q#Y!&)'6TR6\X)IN6#>68LA^^B8"Z.^Y8)])=:%%(,V"L\FJ]?(,&A.1 M\H:TY#%'>/*'!2M\.B.MJ.: G+2++MM"J ME^9#D4_,VG,5P=P,9"3Q 4:"L!+=9.\Q[ES8[)F%Q0I&:UJ-";,"$07&D"&I MS(J2SR(_5P;9'KL@J<<@G_0R-X(&A: D+!"ZT+3#U3$_1&FX+<\50I]IU#]- M VSX'Q8F\BGC]Z91OEJ8ITWCF,?8/%EOG,J2/6G*8IE_5L0_GDE]N9!_N[QH M-6?OEA?U;I@7UJ^)WGB0@B-R%\944/]MM@\;\MH%G0Y!&*$89#\E>VZ#%F_/QY%U7107A M4Z)D]U5,Z7V:8[[X^/7C>GX\.?P .5==>[[%TL^KQK MMB[8SKO_.085X)SIOZ8S&ED'3#X0HD\HM,#B&S#^&G,@G7K5 0F+J'-',M-&Y$%/#5%!>0KJ@HIQG"]97#%0Y[F M=O3!! (;SX6G S#K+%07B9E-BR 3IB&HLL%FN\U^Q!C[-JBA019\,(L,&'@&>?1Q=\HM&Q1KQ9><[D.N9<=4;D M'C?F7?SBXI>[QR\?S&Y=936G.X+FR R/'S%\>2EUF.,R4^Q4L8O=+Z6,.I_? MD]5Y$4IA\L]9=$(?3I!BMJW#*W_SF^SK] M)10 %+EX(<58V&0A;EC?)+B9" MB,1GM9VR'$G^=L(*4(-XX$F6ECIBV_U!9IG](5J7'E5T+&Z,]W!APBM1C!_=T$'@G4G!#!C2,7D6(7" MA&.(,!]&7_@F&L,^VU(.P6Q6 JNV7P,U-L<,,7+;GZU(\&#L$9[*!EAB1"7[ M1"/(I\9+P73"*-*,#9Y'$:+FK(@X41]5*8'AQ([X]_N3U]1_O]7H]EC\\0=X M&(JH*58'G&FKP']MPV@B6ADF7#\YAJ4O.JW&WII1.Z]K%OXZQ&Y4:(":@^1Q MY1@\=H8,;R 5\AEY3F55D82IDE8;H"8R":(B%"Q&"EADPA3.2#4T5#*>*\:3 M/Q+T-W*M0(9-]N/<+'8H'FG%N-9485Y7U"U3K07GX,UL >G?Y4KQ^CTRZ+RP(I>LX D+4-"HQ'3 MS0?:1-#&'%'CRT?_5QSV7WP>X(JC_RMW?IOL9.Y8 MIM1E+FP]85A%+:;(C 2C80O32[N[7OFH "709K%(();W@Y<<5#6P':CRG4UV M.J9]Z'.IS=R+?/08I!Z,K8,=B+E\?4#B8J36J3"Z;7UTK."Q577D+I9Y+L!4 M&['98.UB+$S>8.@WZ5QU_$.7F18 M?\1E4GKY:@N@"C@M?X(Q3T9&,!11TO?5,8^(!*6K/7+*,S5K-W;9N /Y*-&558LCZ# ]%@544BK0PR "FM[9LOPJE)\.Y ]7H N2">R?* MB1I@1LQ.YQXA=U7H6 *E$6C%B6&1VZC;<"P3M+F25RA= M%L]RC.W"%A>V/%788@_\_FP/_+*Y,\3']@SQY^H,\1=*(4-VE#>@THV?>78F MZ#Q3"-1]XCKD?[(34PAR(<*]A@B/%09NKC&LCI%IF7?/#KIS&.&UY^%3J\O< MZG*\0I\W=ZKP\,_NF<%D4)4Q+G\9%F--\ M;"B$?2+:%@^G]%!)-X$[J4<679.MWMML@]]XI]=M?Z]@2DW.;3_6,TJ;F[[% MHY [I[2CT?@9#<>OK[K_X!W78_9%:4F5M/Z]8?P6)ML%G"[@?/*3Q5KP+!C; M$WIS%8.?2B?8KV6 L4#V?*&C]-WL@FOV76_V\-R:QVY,U@Q+89XQ*I/[[_8V M[-:R]8HJB39SVN12TAD^>\A_FF)C#IU3X&\PW33FO9%(T6U!$I_ERE JJP">Z)B6E"8?S9W2L=L+4MUKL7R M3_-^+W1P=LW9M;O;M7^+1-!#2.:8[=R9XW-1<\LV3SA?)'S!MG7F$IT;V+;. M?=HV4W0M&\C$'+Q E$6&BZB''1D*K3$3EJ-%=HXL3U;&8_O$4#TMW<@+BXP"&Z;HA>3/YK">M3LW$:$*'FR@+Z0?Q9R',>V6.A M9D?Y\M4 %MB[K5E@ B>TO-"/,9J\FJ[3"^523%8LE!8K3;TJM(JW4]"95N[ M/WD9\.8LU%45WK49@BMMK=&!_T-V2^;VV!R&_41+O;*PY;_&KTVUV;F@75I7"?/_6 MYN5^$^)'.>RS53=Y.H[4\D#85='0:\#Z;DYC;*%2$A+W)U M.##7A9KYX [[K4/3O($(0Q6(6>0W$1[:4*7=,APJ.T";(YYJT=>"'CS-I\&? M690=VS ;!$REL[U[+P-UF]V#[D(C_) M+[+2#=^^UFAN?5@S^)S\Z]7>JPUCHI2'5'RH MU*_=0G1X 0%8U>Y;!:<0YU3C!:K&5Q'9&UW>*>*0MC]I%4G[$.B//#*)^]>Q0%9Q MS'/N-.9E:\R.>9I5%9HGH7[MM.&%:T.1\"*D:\'O016>3/PU$O>CW<"Y,EQT MK'>L=ZQWK'>L?YZLO\(?=SK.']="1H[USY[U926R7'B[V6J!:F:R;K88M-]O MNM)]OMG*]:]=?_7VB X3OQED;Q=W*>D3VO&LM4;X>WM>]8=&7Z<:#K]UD);# M[X/B]U@$)7S;4_BV'KC^X+<./'^W!0#Z\X)].:[W<0[!;&( WJU[7.0![[#9 MA"YV.YOTXC7KJ9W"PPM@I86MBTA6;N;7!^U6LM^QV7\0U>XL7'-@=V"OE0 < MV.\3[!WD.[M^'<'N-K>>5UCYF\K.S/-2]B6$;*>]W]W2\,U!VT';07L]M-M>VS^H([1=)? YAFSV^AAZ'\*L^%>W=+#F MPGQJL^[R\6TQ[KL=KWO0JJ-QKX.6U4BG',P=S.\0PW6]7J>6Z9DKN#VOZ.VC MX@E+^82>V[37%JAA]39F1B\O-2\VH=NBI [H5K_Z)8XUE_536WV7L]<3>?/V MON=U>YTZFGN';(=LA^R[(7NOELAVQ;CG&,[98IS.57 V5E$H,OU/8N]+<<[ $CO6. M]8[UCO6.]=O.^BO\L;_7K.,57)N*J_=\JRR]#42^TWYM[NNOWE<5BB%6KMG% MTN%UKJ<[:?9X%(N$GGT626ZN,S4O_6!?A9A_"=8_Z?+^ZCK 8/XZP.'T74PZ MQP>Q>4<7W08^+#(,D(&;-EEZUO-MI'K0.KKO]N--L=W>O:]3T]Z^]1GFS@5J= M_2>DZ):W;W;=[9NUN@^C1A<[.]780M58;X[J] %>:L=ZQWK'>L=ZQWK'>L?RZLOVKS<;_IN\- -9#18A+>>90DW%V;_"37)K\O MW]9\.LZ$8#\K\[KFG\SKFB]=AE[K6[7='>@.V [8EX']B5[#?G-<7U6P;3LW M71\T.P0_5P2[UXXXD#J0UA^D*U\N4ANQ.Y ZD#J0.D_J0.I 6G>0/O1KNEYP M)EJ?9Y;+[K^J@9S72JCIZ M60?T+0+ZKM?;J^4+7^N@9S72*@=T!_0[ -W?]WK[^P[G#N>U%(##^3WAO-WQ M=ENUQ+G;=GQ>Q8%_BT1D=/==$C(>QC*1.J=]R'/Q3,X:.$-T*T-4OM<.9JB6 MKR:NC2*Z(THU*ND[LU$/L^%O;Y;BS(8S&\YL/(W9:+>\O?TMK6(ZN^'LAK,; M3V,WNMY>;Z^.9L.=IWB.)1/[SD9UZ;RVJ\H^;S/3]KW=3KN.=J8.6E8CG:IC MQ.%@OBTP/_!Z[:Y#N4-Y+07@4'Y/.QL'WI[O8.Y@7D\!.)C?TTZ$[[5:M8S9 MW4&*YU45^&S>Y5?6 CR6B%L^7^%*D\_)_NSX^^V5K_NHC2*X'06WH^!@NPS; M=JOK8.M@ZV"[7; ]./ =;!UL'6RW"[9[W?T;OQZQTW3;YUN9*'\2.8N4=MOE MSQ;5]!#33MOW]GNW]<8O'JY/[6 =S+8#9H2TKM?R5_O/.LBY1E)U0'- N[4_ MZW2]3JOE8.9@YF#V@##S?6^O>W#3;- _,+.X#=,MS -9*B#.,<\$XWF>R4&1 M\T$D6*Y8H.)8)>;-7#I7P=E81:'(]#_^_LUOM7'*Q.JOPB%9ADY-!ZX$S( MDYN0\EG3?6]_K^OM=K?TDKW'54H7KM1N+\19DII8DLZ^Y^^WO-Y!QUD29TF< M)7&6Y+:69+_C^5W\V7=/QSM+XBR)LR2WMB1^S^NT#[R#>F8W58D&_])Y _/C M.B%___0(?0)V58!.Z\Z;![%>M&9[$J65H:%Y843ZK4/3O!'Q MB2KR_E!^$^'AA0SS,2@PC"H[0)013[7H:Y'RC.>B6K,U0V;L5\O5PW.IY4!& M,I_TJ_XK:H@+T[W:K!ZY=Z,G:5[PV:G'>?GJEMBC!\/<%J^Y?6G-[S#8()/K MUCJ>@C'E(V&1T^!#A!Q]'EWPB;:PK M/5L8>]\Z4VRVV=\?%]I87^T>A.J!BL+Y]?F7N':42;CR5V^/!O NJP*J!Z+L<@RQGC;VB'3= M@&-1)!+.OHPY5A*(PC@C[;3N9K)=S46/?4B")I.:<19QFBVGG;&!5.E"0]HK M2WDR89$PFV=T<;+,-4O4N8B8HE=0H4^D1C)@*08:@C(Z AQ*':!)YE5OKC8[ M:;3Q)K( A(%H-I29)I$U@HAK4&1&$\E?DU@PNI6)IX8(S3 H!AP.95!$.>37 MR&%P%P586;,)K@6NLGL:NT>7N]0@VP>LC1381'D+* =OA"K]5@&FKZ! M#$Z7/H$+09%ET)QHP@;"7 Y]SJ,"+4,F$[ HE>?F]FAP40O680%4Q[ '0X\R M'AL203,SE-%;NID:,I.$@KSQ)!4935= )AZ&6Z#,E8E: Q&*O"7FE_(?,S.9)B("=11)0(L M#L:9 N'5QR7?S!#*7(2E08 J]%P#0]Z4LT9C(JTJL1*OCCY^_-3H[.ZO9H)9 M/$@/1"RYF6D$0TALI:9:Y.8R;C3DX3E/ A"^FDC/+HB7,O#YE/>9"*SH()/< MK+WIC,1-#.U[E5UP9 ?E3HC87S-P422GS.V-S*VM@D1TY>P%C( A:=C( ;6 MQN L0 ,N$\VL@0K0PW(^*CFOIYRW+<)#H_4E6&+!DQ(L].N73))A8%\%K!OMP= E0510 F?!1#B,9 Q:J83#R>??&SXLNB2ITV<2\8#5*9XPP;-(PFU8RQM='DB59I[\O3E+4V16/4L* MEF>88_AL'$.R ^4 K#A@A9E+\]TVXC.(2*AI#0W6IIE4M]$@!8:-N I MX0%1"T+7]4;6ZKD5EYZ9:7JFS6H+QH4_0F1,S6?3E]&BN38TL-93T_)*,PDF MTN#FW:SX%3KY!YI16,Q94L0# :-,ZG/;"/B4$:.P=CP?(S8-E!%!+;R@L@) M\L(HGD;XJVUT/1QB$ A8$.>B2?D>6 3<6N WH]JP[]H$6,0 *!G6"LX OD"L MB3!U :5=SYPF.S7"64>GU0G$90.X$5IGHDIW@N%SU;<1;#X77,*IA$98VIO7 M(R,PI!F1J"S#LKB7U0M-"+B7XGJ,6U*[% :K 9%M'%],]-M?#&D8)(=T3&(# MZX69+;OQ.0+7?'*X9LAE&KFM\I)X1((E!<+2R'.K#"-R_!3W#A'&CR H:P_% M4."?64M&F!\B-U#3+D@-:*X1>%X*5F:@FVYA-N0U_%QF!;"%F!MD M4)I<6'>%%5AAK<&;-P:MQR4]76=-YHQ&&:?: M[->P?JV5@&,1HDSE J,"%/WE$?I60>X)*>=[2^@TK,7 VQ$<+O/OEP(2%QFL M[(DPVHLEOZ=(N]UJ_#)-@?^TK1CI2\C^4\#G=5H>\UO^REO-:QE(>@25"UA$ M^G>FJ<;\SJ)\HZ[>DF^X0E5)\I<"NF*@Q9\% 7D(P"8C;0%(G)S+;FC4G[[! M',(6LG=(.6RD9VH39%BG(<]JMTZE"UT%GN0NJI_+!A9A99T#HJ#UG FJ=2%L MM4:D2$T_,_C\A$42V9G^+&1FO6O$+^ZG#.&V2%[X%DG-'M=XH"+4A^1<('7) M8%;+5 <0AQL*\GXM+2;X-\C>'NEQA)SKI G.#Q"MJ80^_2B'XFL@V5%X3@54 MF,>/']_1%ZW^EZ[7;+V^W=^P)YEOU7A*5H M!$7E2IH();='J1]>:[?NS,V3X_QG$4I>0;O.R YYS(XYT$V__2BR;,+^P>/T MD"(/LR7VI1C0%L[47E$[O^TW_+U.H]OMMNN-[9"6]E\#6E>:;1>LGRA8>?/# M0(63MW][\\,XCZ.W_P]02P$"% ,4 " #@@&I36>9G#J,3 6S $0 M @ $ 86QN82TR,#(Q,3$Q,"YH=&U02P$"% ,4 " #@ M@&I3:P-='A<# #""0 $0 @ '2$P 86QN82TR,#(Q,3$Q M,"YX&UL4$L! A0#% @ X(!J4]4K M!_G.! O"D !4 ( !5AT &%L;F$M,C R,3$Q,3!?<')E M+GAM;%!+ 0(4 Q0 ( ." :E.GWQ)FLQT %"6 0 / " J 5